El interés en corto de Enerpac Tool Group da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Enerpac Tool Group. Los datos de interés en corto se actualizan cada dos semanas.

Enerpac Tool Group (NYSE:EPAC) Bolsa, Informe de interés en corto

Enerpac Tool Group

Enerpac Tool Group Corp provides high-precision tools, controlled-force products, and solutions for precise heavy lifting. The company has one reportable segment, the Industrial Tools & Services (IT&S) Segment. The IT&S segment is engaged in the design, manufacture, and distribution of branded hydraulic and mechanical tools and in providing services and tool rental to the refinery/petrochemical; general industrial; industrial maintenance, repair, and operations (MRO); machining & manufacturing; power generation; infrastructure; mining; and other markets. Geographically, the company has operations in Algeria, Australia, Brazil, France, Germany, Kazakhstan, India, Italy, Japan, Norway, Poland, Saudi Arabia, Singapore, South Africa, South Korea, Spain, and the United Arab Emirates.

KB Home

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

CTRM

EPAC

LUNR

TIVC

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este lunes: KBH, TIVC, LUNR, CTRM y EPAC.

5 acciones en el foco este lunes: KBH, TIVC, LUNR, CTRM y EPAC

Enerpac Tool Group Corp

Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) reported quarterly losses of $(15.65) per share which beat the analyst consensus estimate of $(46.80) by 66.56 percent.

Earnings Beats

ALLR

Allarity Therapeutics FY 2025 GAAP EPS $(15.65) Beats $(46.80) Estimate

ESS Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) reported quarterly losses of $(1.97) per share which missed the analyst consensus estimate of $(1.37) by 43.8 percent. This is a 2088.89 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $2.850 million which missed the analyst consensus estimate of $5.794 million by 50.81 percent. This is a 1.93 percent increase over sales of $2.796 million the same period last year.

Earnings Misses

ESS Tech Q4 2024 GAAP EPS $(1.97) Misses $(1.37) Estimate, Sales $2.850M Miss $5.794M Estimate

BHST

BioHarvest Sciences Inc. - Common Stock Q4 2024 Adj EPS $(0.17) Misses $(0.15) Estimate, Sales $7.30M Miss $9.31M Estimate

ROYAL OAK, Mich., March 31, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE:&nbsp;ADC) (the "Company") today announced the establishment of its inaugural commercial paper program. The program allows the Company, through its subsidiary, Agree Limited Partnership (the "Issuer"), to issue up to $625 million of short-term, unsecured commercial paper notes. The notes will be sold under customary terms in the United States commercial paper note market and will rank pari passu with all the Issuer's other senior unsecured indebtedness. The notes will be fully and unconditionally guaranteed by the Company and certain of its subsidiaries. Note proceeds will be used for general corporate purposes.
The commercial paper program further diversifies and strengthens the Company's balance sheet by providing another source of short-term capital. The Company expects to realize cost benefits in the commercial paper market versus its $1.25 billion revolving credit facility, and it expects to use its revolving credit facility as a liquidity backstop for the repayment of the notes issued under the commercial paper program.
The notes and guarantees to be offered under the commercial paper program have not been and will not be registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes under the Issuer's commercial paper program.

Agree Realty Establishes $625M Commercial Paper Program

Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) reported quarterly losses of $(3.83) per share which missed the analyst consensus estimate of $(3.00) by 27.67 percent.

AQMS

Aqua Metals FY 2024 GAAP EPS $(3.83) Misses $(3.00) Estimate

Progress Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) reported quarterly earnings of $1.31 per share which beat the analyst consensus estimate of $1.06 by 23.58 percent. This is a 4.8 percent increase over earnings of $1.25 per share from the same period last year. The company reported quarterly sales of $238.01 million which beat the analyst consensus estimate of $235.63 million by 1.01 percent. This is a 28.88 percent increase over sales of $184.69 million the same period last year.

PRGS

Progress Software Q1 2025 Adj EPS $1.31 Beats $1.06 Estimate, Sales $238.01M Beat $235.63M Estimate

VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) reported quarterly sales of $1.200 million which missed the analyst consensus estimate of $1.796 million by 33.18 percent.

VNRX

VolitionRX FY Sales $1.200M Miss $1.796M Estimate

LPRO

Open Lending Q4 2024 GAAP EPS $1.21 Beats $0.02 Estimate, Sales $(56.90M) Miss $23.65M Estimate

Biotech

General

CNTB

Connect Biopharma Reports Data From Global Phase 2 Trial Of Rademikibart In Patients With Moderate-To-Severe Uncontrolled Asthma

Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.16) by 56.25 percent. This is a 72 percent increase over losses of $(0.25) per share from the same period last year.

TLPH

Talphera Q4 2024 GAAP EPS $(0.07) Beats $(0.16) Estimate

Guidance

SONM

Sonim Technologies FY24 EPS ($7.13) Down From ($0.02) YoY; Revenue $58.29M Down From $93.63M YoY.

Spruce Power Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>) reported quarterly losses of $(0.29) per share. This is a 81.88 percent increase over losses of $(1.60) per share from the same period last year. The company reported quarterly sales of $20.23 million which beat the analyst consensus estimate of $17.40 million by 16.24 percent. This is a 28.82 percent increase over sales of $15.70 million the same period last year.

Spruce Power Holding Corporation Class A Common Stock

SPRU

Spruce Power Holding Q4 2024 GAAP EPS $(0.29) Up From $(1.60) YoY, Sales $20.23M Beat $17.40M Estimate

Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.25) by 8 percent. This is unchanged from the same period last year.

RANI

Rani Therapeutics Hldgs Q4 2024 GAAP EPS $(0.27) Misses $(0.25) Estimate

Management

Open Lending Appoints Jessica Buss As CEO And Michelle Glasl As COO, Effective Immediately

Tucker served as interim CEO since February 2025 after being hired as chief financial officer for the company in November 2024, which followed a previous tenure as CFO of Jack in the Box from March 2018 to September 2020.
 &nbsp;

JACK

Jack In The Box Names Lance Tucker As CEO; Tucker Served As Interim CEO Since February 2025

Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.82) by 23.17 percent. This is unchanged from the same period last year.

OMER

Omeros Q4 2024 GAAP EPS $(0.63) Beats $(0.82) Estimate

Construction is scheduled to begin in Summer 2025 with substantial completion anticipated in Spring 2030.
 &nbsp;

Contracts

Fluor Secures Construction Contract For The State Highway 6 Project In College Station, Texas; To Recognize The $671M Bid-Build Contract In Q1 Of 2025

RCAT

Red Cat Holdings 2024 Transition Period EPS $(0.57); Revenue $4.9M

GDEV

GDEV Q4 Revenue $98M Down From $109M QoQ.

TransCon CNP is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly and designed to treat individuals with achondroplasia by providing continuous exposure of active CNP to receptors on tissues throughout the body, including growth plates and skeletal muscle.

Comments

Enerpac Tool Group

Interés en corto

Enerpac Tool Group (NYSE:EPAC) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL